

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/44887092>

Identification of Disulfide Bonds in Protein Proteolytic Degradation Products Using de novo-Protein Unique Sequence Tags Approach

ARTICLE *in* JOURNAL OF PROTEOME RESEARCH · AUGUST 2010

Impact Factor: 4.25 · DOI: 10.1021/pr1002559 · Source: PubMed

CITATIONS

6

READS

15

4 AUTHORS, INCLUDING:



Yufeng Shen

Pacific Northwest National Laboratory

113 PUBLICATIONS 8,785 CITATIONS

SEE PROFILE



Sam O Purvine

Pacific Northwest National Laboratory

82 PUBLICATIONS 3,446 CITATIONS

SEE PROFILE



Richard D Smith

Pacific Northwest National Laboratory

1,131 PUBLICATIONS 45,995 CITATIONS

SEE PROFILE

Published in final edited form as:

J Proteome Res. 2010 August 6; 9(8): 4053–4060. doi:10.1021/pr1002559.

Identification of disulfide bonds in protein proteolytic degradation products using the *de novo*-protein unique sequence tags approach

Yufeng Shen¹, Nikola Tolić², Samuel O. Purvine², and Richard D. Smith^{1,2}

¹Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354

²Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA 99354

Abstract

Disulfide bonds are a form of posttranslational modification that often determines protein structure (s) and function(s). In this work, we report a mass spectrometry method for identification of disulfides in degradation products of proteins, and specifically endogenous peptides in the human blood plasma peptidome. LC-Fourier transform tandem mass spectrometry (FT MS/MS) was used for acquiring mass spectra that were *de novo* sequenced and then searched against the IPI human protein database. Through the use of unique sequence tags (UStags) we unambiguously correlated the spectra to specific database proteins. Examination of the UStags' prefix and/or suffix sequences that contain cysteine(s) in conjunction with sequences of the UStags-specified database proteins is shown to enable the unambiguous determination of disulfide bonds. Using this method, we identified the intermolecular and intramolecular disulfides in human blood plasma peptidome peptides that have molecular weights of up to ~10 kDa.

INTRODUCTION

Polypeptides often achieve their stable conformations through formation of disulfides, and the mechanisms for formation of disulfides have been recently reviewed (1,2). The physiological and pathological relevance of disulfides to diseases and protein functions has been increasingly recognized for e.g. tumor immunity (3), hemostasis (4), cell death and neurodegenerative diseases (5), growth factors (6), G-protein-receptors (7), etc.

Determination of disulfides can be accomplished using X-ray crystallography (8) and NMR (9) analyses, but typically requires purified proteins having known sequences. Mass spectrometry (MS) enables identification of disulfides (10) and advances have been reported for working with complex mixtures of proteins (11–14). For example, Nair *et al.* used *de novo* sequencing to find disulfides in peptide Mo1274 from FT MS/MS spectra (11), Xu *et al.* investigated using the MassMatrix search engine for identification of disulfides from LC-LTQ spectra (12), Tiptom *et al.* analyzed disulfides in the GM2 protein activator protein (GM2AP) using LC-FT MS/MS (13), and Wu *et al.* analyzed the disulfides in tryptic peptides of three proteins (14). Due to the limited options for disulfide analysis using widely applied database searching programs, such as SEQUEST and Mascot, Choi *et al.* developed their own algorithm “DBond” for database searching of disulfides using Q-TOF spectra (15). However, reported studies were limited to known or standard model peptides and proteins (11–15), and this approach has not yet been demonstrated for proteomic or peptidomic analysis. Thus,

databases used were very small, and e.g., the custom databases only incorporated sequences of the model proteins (12,13), and “enzyme rules” were needed for effective identification of disulfides in peptides through the database search (15). All these factors affect the methods developed for practical proteomic and peptidomic analyses that require searching huge numbers of spectra against large databases. Proteomics analysis commonly applies reduction/alkylation of cysteine residues in peptides generated by exogenous enzymes (e.g., trypsin), while there are few reports for peptidomic analysis for which there are no enzyme rules that can be applied to reduce the number of analysis targets.

In this work, we describe a *de novo* sequencing-UStags approach for identification of disulfide bonded species in the blood plasma peptidome peptides, as they can be potential biomarker candidates. Additionally, the methodology developed for the human blood plasma peptidome peptides can be applied for various types of applications, as the blood plasma peptidome peptides can have a large MW range of 1,000–15,000 Da, carry various charges (e.g., 1–15), and have termini of any of the amino acids (16). We show that the use of UStags greatly simplifies identification of both intramolecular and intermolecular disulfide bond species by searching large FT MS/MS spectral datasets against the large IPI human protein database and without the need to define (or assume) the peptide termini.

METHODS

Description of the FT MS/MS spectra datasets

The FT MS/MS spectral datasets used in this work have been submitted to the public repository pride (<http://www.ebi.ac.uk/pride/>). These datasets were obtained using LC-Orbitrap MS/MS analysis of the human blood plasma peptidome. The peptidome was isolated from early-stage breast cancer patients and healthy individuals using the method previously described (16). Briefly, the plasma sample was first depleted of its 12 high-abundance proteins using a 12.7 × 79.0 mm IgY12 LC10 AC column (Beckman Coulter, Fullerton, CA) according to the manufacturer’s recommendations. The AC flow through fraction (i.e., the depleted sample) was separated with use of a Superdex 200 10/300 GL SEC column (GE Healthcare, Piscataway, NJ). Based on the elution time calibrated with standard proteins beta-galactosidase, phosphorylase, bovine serum albumin, carbonic anhydrase, beta-lactoglobulin, and cytochrome *c* (Sigma-Aldrich, St. Louis, MO), the peptidome <20 kDa species were collected, and the contents of the resultant peptidome species were determined by BCA assay (Pierce, Rockford, IL). The isolated peptidome species (50 µg) were separated using HRLC equipped with a 100 cm × 100 µm i.d. capillary column that was manufactured in our lab with use of 3-µm porous (300 Å size) C4-bonded silica particles (Sepax Technologies, Inc. Newark, DE). The flow rate measured with the mobile phase A (acetonitrile/H₂O/acetic acid, 10:90:0.2, v/v/v) was 0.5 µl/min. The separation was completed with a mobile phase gradient from mobile phase A to 70% B (acetonitrile/isopropyl alcohol/H₂O/acetic acid/trifluoroacetic acid, 60:30:10:0.2:0.1, v/v/v/v/v) in 1600 min (the exponent gradient was generated in a static mixer under a constant pressure of 13.000 psi and room temperature). Two LC-MS/MS runs were performed for each sample, and all spectra collected were given in the public repository pride. The separated components were analyzed with an LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific., San Jose, CA), and the spectra were collected at a 60K resolution for both survey scans and the following MS/MS. A survey scan with $400 \leq m/z \leq 2000$ was followed by FT MS/MS of the 5 most intense ions from the survey scan (monoisotopic precursor selection not enabled). FT MS measurements with 3 micro scans were applied for all FT MS/MS analyses, and the minimum signal required for a selected precursor ion to trigger a subsequent MS/MS scan was set to 500. FT MS/MS employed 35% normalized collision energy for CID. Mass calibration was performed prior to analysis according to the method recommended by the instrument manufacturer. The same mass spectrometry conditions were

used for analyses of various sizes of the peptidome components (isolated with a cutoff of 20 kDa), regardless of the presence of disulfide bonds.

The computational tools and methods

Figure 1 shows the flowchart for use of the *de novo*-UStags approach (17) to determine disulfides. Briefly, *de novo* sequencing was based on the monoisotopic masses de-isotoped from the Orbitrap FT MS/MS spectra using software ICR2LS (<http://ncrr.pnl.gov/software/ICR2LS.stm>). A mass error tolerance of 0.005 u was used for sequencing, and no gaps of >1 amino acid residues were allowed. The generated amino acid sequences were matched to the IPI human protein database (ipi.HUMAN.v3.39, <ftp://ftp.ebi.ac.uk/pub/databases/IPI/>, containing 69,731 sequence entries) to inspect for the sequence uniqueness (i.e., the criterion for establishing a UStag). If the sequences uniquely belong to specific proteins, they are referred as UStags; otherwise, the sequences were not accepted for identifications. Once UStags were obtained, the theoretical mass values of the UStag prefixes and suffixes were calculated according to the location of the UStags among the UStags-specified database protein sequences; the experimental mass values of the UStag prefixes were derived from masses of the smallest fragments in the UStags and the experimental mass values of the UStag suffixes were determined from the mass differences between the precursor and largest fragment. When the differences between the experimental and theoretical values were $-2n \times 1.008$ u and the UStag prefix and/or suffix contained $2n$ Cys (n : 1, 2, 3, ...), disulfides were directly assigned for the sequences. When the UStag prefix or suffix contained $(2n-1)$ Cys, the mass differences were calculated and searched against the database sequence specified by the UStag (the pseudo-algorithm is given in Table 1). The mass agreement (i.e., <10 ppm mass error) determines the two pieces of sequences linked by the disulfide bridge. All spectra that generated the UStags, but had the prefixes and suffixes not agreeing with the database predictions, were used for identification of peptides that contain disulfide bonds, and no a minimum number of counts required for individual MS/MS spectra.

RESULTS

We identified 58 plasma peptidome peptides that contain the disulfide bonds among the ~990 in total modified and non-modified peptides identified (not shown). Table 2 shows examples of disulfides-containing peptidome peptides identified from the human blood plasma peptidome using the *de novo*-UStags approach. The disulfides identified can be classified into 3 categories: the intramolecular disulfides that are situated in the single peptide sequences, the intramolecular disulfides that link two pieces of separate sequences belonging to the same molecule of the protein, and the intermolecular disulfides that link two pieces of separate sequences belonging to the different molecules of the protein. Determinations of these disulfides are demonstrated below with examples, showing that identification of disulfides from complex mixtures by searching large (i.e., IPI human) protein database can be greatly simplified by use of the *de novo*-UStags approach.

Figure 2 shows an identification of a disulfide bridge that links two separate sequences originating from the same molecule of the protein. The amino acid sequence SASMMYQE was *de novo* sequenced and this sequence is a UStag (Ser280–Glu287) of antithrombin-III (AT). The fragments used for sequencing of the UStag are located as the consecutive y_4 – y_{12} ions (labeled in the figure) counted from AT Arg291, and the UStag has a prefix sequence of GKFR. Extending the UStag suffix sequence from Ser280 towards the N-terminal direction generates a new sequence Cys279–Arg291 (CSASMMYQEGKFR) that contains one Cys residue (Cys279). This sequence has a mass value (mono isotopic, the same below except for the specified) of 1536.652 u, smaller than the precursor measurement (7272.697 u). The mass difference (5736.045 u) is searched against the masses that are generated by combination of

the sequences extended from Cys279 towards the N-terminal direction with all pieces of the Cys-containing AT sequences. The searching outputs sequence Lys268–Ser278 (KELFYKADGES) extended from Cys279 plus another piece of sequence Ser426–Lys464 (SLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK) that contains Cys462. Therefore, the peptide is determined as to be constructed by two sequences Lys268–Arg291 and Ser426–Lys464 linked by a disulfide bridge Cys279–Cys462. The identified peptide has a molecular mass in agreement with the precursor measurement (e.g., ~1.0 ppm mass error, see the labels inserted in the figure) and explains additional abundant ions as fragments y56–y61 (counted from Arg291 and including sequence Ser426–Lys464; these fragments construct sequence KELFYKAD between Lys268 and Ser278, see those labeled in the figure). The disulfide bridge Cys279–Cys462 has been reported within AT (18), and therefore, the two different sequences linked by the identified disulfide bridge originate from the same AT molecules.

Figure 3 shows the identification of a disulfide bridge that apparently links two separate sequences originating from different protein molecules. The sequence AQYWLK was *de novo* sequenced, and it is a UStag (Ala466–Gly472) of vitronectin (VN). This UStag is sequenced from C- to N-terminal direction, but consecutive ions used for sequencing cannot be located in the VN database sequence. This means that the UStag prefix differs from VN database sequence. Extending the UStag prefix sequence from Gly472 toward to the C-terminal direction generates a new sequence that contains one Cys residue (Cys473). Further extending the sequence to the C terminus Leu478 of VN has a mass of 693.327 u, smaller than the neutral mass of the smallest ion (2303.089 u) used for sequencing of the UStag. The mass difference (1609.762 u) is searched against all pieces of Cys-containing VN sequences. The searching outputs a combination of the UStag suffix sequence Ser464–Ile465 (SI) and another VN sequence (Ser464–Leu478) SIAQYWLKCPAPGHL that contains Cys473. Therefore, the peptide is identified as to be constructed from two Ser464–Leu478 sequences linked by a disulfide Cys473–Cys473. This identified peptide has a molecular mass agreeing with the precursor measurement (e.g., ~0.9 ppm mass error, see measurements labeled in the figure), explains the UStag sequence as fragments y7–y13 (counted from the VN C terminus and including Ala466–Leu478), and explains additional low mass and other abundant ions in the MS/MS spectrum as y and b fragments (see those labeled in the figure).

Determination of disulfide bridge(s) situated in the single-sequence peptides is a special situation of the *de novo*-UStags method, i.e., the determination is simply achieved with extension of the UStag prefix and/or suffix, as illustrated in Figure 4. The UStag DLGDGTEEE was *de novo* sequenced for prothrombin (FII) (Asp305–Glu297), and is constructed by fragments y10–y19 counted from FII Arg314. Extending the UStag suffix sequence to Ser199 directly leads to identification of three intramolecular disulfides in a single sequence peptide. The peptide (Ser199–Arg314) identified is a truncation of the intact FII activation peptide-2 (Ser199–Arg327) (19).

Identification of disulfide bonds in the peptidome peptides can reveal the protein structures arising from degradation, as shown in Figure 5. VN has been reported to exist as monomer and dimer in human blood plasma through formation of a disulfide bond (20). Using the *de novo*-UStag FT MS/MS analysis, we first find evidence that the disulfide bond responsible for formation of the VN dimer is the C terminal Cys473–Cys473 (Figure 4) between two VN molecules (Figure 5A). AT is a protease inhibitor to inhibit the protease (e.g., thrombin) proteolytic activities, and its inhibitory reaction site is at Arg425–Ser426 (21). Cleaving the inhibitory Arg425–Ser426 bond by degradation will lead to loss of the AT inhibitory function. Figure 5B shows an identified disulfide bond that links the sequence (Ser426–Lys464) containing the broken AT inhibitory bond to another piece of AT sequence (Lys268–Arg291). This reveals that AT should retain its structure during degradation of the sequence loop defined

by the disulfide bond. A different situation is shown in Figure 5C for plasminogen preactivation peptide. This preactivation peptide has sequence loops that are formed by two disulfide bonds (22). Degradation cleavage occurs not to the loop sequence, but to the C terminal truncation of the preactivation peptide. Disulfide bonds also have functions to link different protein sequence domains. As shown in Figure 5D, C3 α and C3 β in C3b of the third complement component are linked by disulfide bonds (23). We detected the disulfide bonds within C3 β (Table 2), but not that linking C3 α and C3 β , which suggests that C3b degradation occurs after disruption of the interchain disulfide bonds.

DISCUSSION

The present results show that use of the UStags enables improving identification of disulfides through assignment of spectra to specific proteins from a large protein sequence database (e.g., IPI human protein database). Once spectra and proteins are specifically related by UStags, the protein sequences suggested by the database can be examined for disulfide bonds (and also other modifications) without the need for searching of all spectra against the large proteome database in conjunction with consideration of a range of other modifications for these species. The UStags identification is founded upon the accurate measurements provided by FT MS/MS; we did not find any incorrect UStags for the datasets tested (>100,000 FT MS/MS spectra) based upon examination with a decoy database (i.e., re-constructed from the IPI human protein database used for identification by reversing each protein sequence). The peptidome peptides containing the intermolecular and intramolecular disulfides identified by the *de novo*-UStags approach have molecular masses up to ~14,000 u and can incorporate termini of various amino acids. Arg and Lys are the residues mainly found for the P1 site of the disulfide-containing peptides identified, which is similar to that observed for overall peptides identified from the blood plasma peptidome (16). Plasmin may be one of the major proteases responsible for observation of the trypsin-like cleavage feature. In this work the longest Cys-containing sequences obtained from the *de novo* sequencing had 6 residues, and they are not the UStags (i.e., they belong to different IPI database proteins) and not used for the unambiguous identification in this work. Electron-transfer dissociation may be an alternative method for improving the fragmentation of disulfide-containing peptides (14,24), and we are now evaluating different dissociation methods for analysis of blood plasma peptidome peptides including those containing disulfide bonds.

High temperature, alkaline pH, and air-catalyzed oxidation can lead to changes of disulfides to form the lysinoalanyl crosslink, undergo hydrolysis to yield sulfhydryl groups and other products, and initiate thiol-disulfide interchanges (25). In this work, we analyzed disulfides-containing peptides in the blood plasma peptidome without implement of special protections of the disulfide bonds. We examined the disulfide bridges identified with reference to the UniProt protein structural information (<http://www.uniprot.org/>). All disulfide bridges identified are in agreement with the UniProt information except for the VN dimer, for which no information for VN Cys473 is available. Blood VN dimer is well known and it is reasonable for observation that the disulfide bridge is responsible for the dimer as free cysteine is difficult to be retained in the protein crosslink polymers. The process of the disulfide formation, i.e., the disulfide bond leading to formation of dimer or first formation of dimer and then the disulfide bond through interchange, keeps unknown.


Acknowledgments

Portions of this research were supported by the U.S. Department of Energy Office of Biological and Environmental Research (DOE/BER) and the NIH National Center for Research Resources (RR18522). Work was performed in the Environmental Molecular Science Laboratory, a DOE/BER national scientific user facility located on the campus of Pacific Northwest National Laboratory (PNNL) in Richland, Washington. PNNL is a multi-program national laboratory operated by Battelle Memorial Institute for the DOE under contract DE-AC05-76RLO-1830.


References

1. Christis C, Lubsen NH, Braakman I. Protein folding includes oligomerization – examples from the endoplasmic reticulum and cytosol. *FEBS J.* 2008; 275:4700–4727. [PubMed: 18680510]
2. Riemer J, Bulleid N, Herrmann JM. Disulfide formation in the ER and mitochondria: two solutions to a common process. *Science.* 2009; 324:1284–1287. [PubMed: 19498160]
3. Dranoff G. Targets of protective tumor immunity. *Ann N Y Acad Sci.* 2009; 1174:74–80. [PubMed: 19769739]
4. Hogg PJ. Contribution of allosteric disulfide bonds to regulation of hemostasis. *J Thromb Haemost.* 2009; 7:12–16.
5. Nakamura T, Lipton SA. Cell death: protein misfolding and neurodegenerative diseases. *Apoptosis.* 2009; 14:455–468. [PubMed: 19130231]
6. Guo Q, Manolopoulou M, Bian Y, Schilling AB, Tang W-J. Molecular basis for the recognition and cleavages of IGF-II, TGF- α , and amylin by human insulin-degrading enzyme. *J Mol Biol.* 2009; 10.1016/j.jmb.2009.10.072
7. Wess J, Han S-J, Kim S-K, Jacobson KA, Li JH. Conformational changes involved in G-protein-coupled-receptor activation. *Trends Pharmacol Sci.* 2008; 29:616–625. [PubMed: 18838178]
8. Jones TA, Kjeldgaard M. Electron-density map interpretation. *Methods Enzymol.* 1997; 277:173–208. [PubMed: 18488310]
9. Klaus W, Broger C, Gerber P, Senn H. Determination of the disulphide bonding pattern in proteins by local and global analysis of nuclear magnetic resonance data. Application to flaviridin. *J Mol Biol.* 1993; 232:897–906. [PubMed: 8355276]
10. Gorman JJ, Wallis TP, Pitt JJ. Protein disulfide bond determination by mass spectrometry. *Mass Spectrom Rev.* 2002; 21:183–216. [PubMed: 12476442]
11. Nair SS, Nilsson CL, Emmett MR, Schaub TM, Gowd KH, Thakur SS, Krishnan KS, Balaram P, Marshall AG. De Novo sequencing and disulfide mapping of a bromotryptophan-containing conotoxin by Fourier transform ion cyclotron resonance mass spectrometry. *Anal Chem.* 2006; 78:8082–8088. [PubMed: 17134143]
12. Xu H, Zhang L, Freitas MA. Identification and characterization of disulfide bonds in proteins and peptides from tandem MS data by use of the MassMatrix MS/MS search engine. *J Proteome Res.* 2008; 7:138–144. [PubMed: 18072732]
13. Tipton JD, Carter JD, Mathias JD, Emmett MR, Franucci GE, Marshall AG. Sequential proteolysis and high-field FTICR MS to determine disulfide connectivity and 4-maleimide TEMPO spin-label location in L126C GM2 activator protein. *Anal Chem.* 2009; 81:7611–7617. [PubMed: 19689113]
14. Wu SL, Jiang H, Lu Q, Dai S, Hancock WS, Karger BL. *Anal Chem.* 2009; 81:112–122. [PubMed: 19117448]
15. Choi S, Jeong J, Na S, Lee HS, Kim H-Y, Lee K-J, Paek E. New algorithm for the identification of intact disulfide linkages based on fragmentation characteristics in tandem mass spectra. *J Proteome Res.* 2010; 9:626–635. [PubMed: 19902913]
16. Shen Y, Liu T, Tolić N, Petritis BO, Zhao R, Moore RJ, Purvine SO, Camp DG II, Smith RD. Strategy for degradomic-peptidomic analysis of human blood plasma. *J Proteome Res.* 10.1021/pr901083m
17. Shen Y, Tolić N, Hixson KK, Purvine SO, Anderson GA, Smith RD. De novo sequencing of unique sequence tags for discovery of post-translational modifications of proteins. *Anal Chem.* 2008; 80:7742–7754. [PubMed: 18783246]
18. Petersen, TE.; Dudek-Wojciechowska, G.; Sottrup-Jensen, L.; Magnusson, S. Primary structure of antithrombin-III (heparin cofactor). Partial homology between alpha-1-antitrypsin and antithrombin-III. In: Collen, D.; Wiman, B.; Verstraete, M., editors. *The physiological inhibitors of blood coagulation and fibrinolysis.* Elsevier; Amsterdam: 1979. p. 43-54.
19. Rabiet MJ, Blashill A, Furie B, Furie BC. Prothrombin fragment 1•2•3, a major product of prothrombin activation in human plasma. *J Biol Chem.* 1986; 261:13210–13215. [PubMed: 3759958]
20. Dahlbäck B, Podack ER. Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. *Biochemistry.* 1985; 24:2368–2374. [PubMed: 2581612]

21. Jörnvall H, Fish WW, Björk I. The thrombin cleavage site in bovine antithrombin. FEBS Lett. 1979; 106:358–362. [PubMed: 499520]
22. Wiman B. Primary structure of peptides released during activation of human plasminogen by urokinase. Eur J Biochem. 1973; 39:109. [PubMed: 4770784]
23. Janatova J. Detection of disulfide bonds and localization of interchain linkages in the their (C3) and the forth (C4) components of human complement. Biochem J. 1986; 233:819–825. [PubMed: 3707529]
24. Ueberheide BM, Fenyö D, Alewood PF, Chait BT. Rapid sensitive analysis of cysteine rich peptide venom components. Proc Natl Acad Sci. 2009; 106:6910–6915. [PubMed: 19380747]
25. Swaisgood HE. The importance of disulfide bridging. Biotechnol Adv. 2005; 23:71–73. [PubMed: 15610967]

**Figure 1.**

The flowchart of *de novo*-UStags approach for identification of disulfides in peptidome peptides. The dark blue segment of the blue loop-like diagram represents the UStag. Explanation of the flowchart is described in the text.






Figure 3. The example showing the *de novo*-UStags approach for identification of an intermolecular disulfide that links two pieces of separate sequences originated from two human blood plasma vitronectin (VN) molecules. Explanation of the identification is described in the text.




Figure 4. The example showing the *de novo*-UStags approach for identification of an intramolecular disulfide within a single piece of sequence of prothrombin (FIL). Explanation of the identification is described in the text.




Figure 5.

Human plasma protein structures through identification of disulfide bonds in the degradation products. (A) Vitronectin dimer is formed by a Cys-Cys disulfide bond that linked the C terminal regions of the two protein molecules. (B) Antithrombin inhibitor inhibitory site degrades together with other sequence. (C) Plasminogen activation peptide degrades on the outside sequence of the disulfide bonds-linked sequence loop. (D) The protein state during degradation can be uncovered through identification of disulfide bond(s). Descriptions are detailed in the text.

Table 1

Pseudo code for searching disulfide(s) within the UStag-specified proteins with anchor sequences.

```

FUNCTION FindDisulfides (Pept, Prot, dM, Prec)

    CONST dMCys := -1.007825 - mass modification on Cys-residue

Input

    Pept - anchor peptide sequence (contains at least 1 Cys)
    Prot - protein sequence containing Pept
    dM - mass difference to explain (k * dMCys: k=1,2,3,...)
    Prec - mass precision in amu (0.005)

Output

    Disulfides - array of disulfides explaining dM in Pept-Prot
    context

Main Loop

    cntC - count of Cys residues in prefix and suffix part of Pept
    Pept1 - Prot predicted peptide linked to Pept via disulfide bond
    Pept1M - expected mass of Pept1
    IF (cntC MOD 2 = 0) THEN
        FOR i := 1 TO cntC \ 2
            IF Abs(dM - i * 2 * dMCys) < Prec THEN
                [Pept & "d-bond" & i] -> Disulfides
            END IF
        END FOR
    ELSE
        CPos := Find 1st Cys in (Prot-Pept); -1 if not found
        DO WHILE CPos > 0
            Pept1M := dM - dMCys
            i := 0
            DO WHILE Pept1M > (dM - (cntC - 1) * dMCys - Prec)
                GENERATE all sequences Seq around CPos such that
                    Abs(Pept1M - SeqM) < Prec
                IF i > 0 THEN
                    [[Pept & "d-bond" & i] & "d-bond" & Seq] ->
Disulfides
                ELSE
                    [Pept & "d-bond" & Seq] -> Disulfides
                END IF
                Pept1M := dM - 2 * dMCys
                i := i - 1
            LOOP
            CPos := Find next Cys in (Prot-Pept); -1 if not found
        LOOP
    END IF
    RETURN Disulfides

```

Table 2

Some of disulfides identified in the human blood plasma peptidome peptides.*

Peptidome peptides	Protein_ origin	UStag	MW (Da)	CS	ME
R.KELFYKADGESC (-dehydro) SASMMYQEGKFR.Y; K.ANRPFLVFIREVPLNTIIFMGRVANPC (-dehydro)VK.-	Antithrombin III	ELFYKAD	6116.076	6	0.07
R.KELFYKAD (-reduction) GESG(-dehydro) SASMMYQEGKFR.Y; L.NRVTFKANRPFLV FIREVPLNTIIFMGRVANPC (-dehydro)VK.-	Antithrombin III	ELFYKA	7072.595	7	0.54
R.KELFYKADGESC (-dehydro) SASMMYQEGKFR.Y; R.SLNPNRVTFKANRPFLV FIREVPLNTIIFMGRVANPC (-dehydro)VK.-	Antithrombin III	SASMMYQE	7272.711	7	1.83
R.TGKEKVTSGSTTTTRRSC (-dehydro) SKTVTKTVIGPDGHKE VTKEVVTSEDGSDC (-dehydro) PEAMDGLTSLGIGTLDGFRHRHP DEAAFFDTASTGKTFPGFF SPMLGEFVSETESRGSESGI FTNTKESSSHHPGIAEFPSRGK.S	Fibrinogen α	LGEFVSE	13994.71	13	0.28
R.KELFYKADGESC (-dehydro) SASMMYQEGKFR.Y; R.SLNPNRVTFKANRPFL VFIREVPLNTIIFM (-hydroxylation) GRVANPC(dehydro)VK.-	Antithrombin III	SASMMYQE	7288.706	7	0.56
R.SIAQYWLGC(-dehydro)PAPGHL.-; R.SIAQYWLGC(-dehydro)PAPGHL.-	Vitronectin	AQYWLG	3221.558	3	1.52
R.KELFYKADGESC (-dehydro) SASMMYQEGKFR.Y; R.VANPC(-dehydro)VK.-	Antithrombin III	SMMYQE	3531.630	4	4.79
K.SGQSEDRQPVPGQQM TLKIEGDHGARVVLVAVDKGV FVLNKKNKLTQSKIWDVVE KADIGC(-dehydro) TPGSGKDYAGVFSDAG LTFTSSSGQQTAAQRAELQC (-dehydro)PQPAA.R	C3 β	WDVVEKADIG	10666.37	6	0.98
R.SEGSSVNLSPPLEQC (-dehydro) VPDRGQQYQGR LAVTTHGLPC (-dehydro)LAWASQAQKALSKH QDFNSAVQLVENFC (-dehydro) RNPDGDEEGVWC (-dehydro) YVAGKPGDFGYC (-dehydro) DLNYC(-dehydro) EEAVEETGDGLDESDRAIEGR.T	Prothrombin	EEETGD	12599.68	7	0.95

Peptidome peptides	Protein origin	UStag	MW (Da)	CS	ME
R.SVPPSASHVAPTETFTYE WTVPKVEGPTNADPVC (-dehydro) LAKMYYSADVPTKDIFTGLIGPM (-hydroxylation) KIC(-dehydro) KKGSLHANGRQKDVVK EFYLFPTVFDENESLLEDNIR.M	Ceruloplasmin	SLLLEDNIR	10929.41	9	0.59
R.SEGSSVNLSPPLEQC (-dehydro) VPDRGQQYQGR LAVTTHGLPC (-dehydro) LAWASAAKALSKHQDFNSAVQLVENFC (-dehydro) RNPDGDEEGVWC (-dehydro) YVAGKPGDFGYC(-dehydro) DLNYC(-dehydro) EEAVEEETGDGLDESDRAIEGR.T_(hydroxylation)	Prothrombin	EAVEEETGD	12615.68	7	2.64
Q.KPRLLLFSPSVVHL GVPLSVGVQLQDVPRGQV VKGSVFLRNPSRNNVPC (-dehydro) SPKVDFTLSSERDFAL LSLQVPLKDAKSC (-dehydro) GLHQLLRGPEVQLVAHSPWL KDSLRS.T	C4	SVGVQL	11393.22	10	0.35
R.RSC(-dehydro) SKTVTKTVIGPDGHKEV TKEVVTSEDGSDC (-dehydro) PEAMDGLTSLGIGTLDGFR HRHPDEAAFFDTAS TGKTFPGFFSPM (-hydroxylation) LGEFVSETESRGSESGIFT NTKESSSHHPGIAEFPSRGK.S	Fibrinogen α	LGEFVSE	12475.91	12	3.31
R.SVPPSASHVAPTETFT YEWTVPKVEGPTNADPVC (-dehydro) LAKMYYSADVPTKDI FTGLIGPMKIC(-dehydro) KKGSLHANGRQKDVVK FYLFPTVFDENESLLEDNIR.M	Ceruloplasmin	ENESLLE	10913.42	7	0.05
R.TGKEKVTSGSTTTTRRSC (-dehydro) SKTVTKTVIGPDGHK EVTKEVVTSEDGSDC (-dehydro) PEAMDGLTSLGIGTLDGF RHRHPDEAAFFDTAST GKTFPGFFSPM(-hydroxylation) LGEFVSETESRGSES GIFTNTKESSSHHPGIAEFPSRGK.S	Fibrinogen α	LGEFVSETE	14010.70	13	0.66
A.IQRTPKIQVYSR HPAENGKSNFLNC (-dehydro) YVSGFHPSDIEVDLLKN GERIEKVEHSDLSFSKDW SFYLLYYTEFTPEKDEYAC (-dehydro) RVNHVTLSPKIVKWDRDI (->M-oxidation).-	β -microglobulin	IVKWDRD	11737.77	7	0.89

Peptidome peptides	Protein_origin	UStag	MW (Da)	CS	ME
R.SEGSSVNLSPLEQC (-dehydro) VPDRGQQYQGRLAVTTHGLPC (-dehydro) LAWASAQAKALSKH QDFNSAVQLVENFC (-dehydro) RNPDGDEEGVWC (-dehydro) YVAGKPGDFGYC (-dehydro) DLNYC(-dehydro) EEAVEEETGDGLDESDR.A	Prothrombin	TGDGLD	12073.40	7	1.28
A.IQRTPKIQVYSRHP AENGKSNFLNC (-dehydro) YVSGFHPSDIEVDLLK NGERIEKVEHSDLSFSKD WSFYLLYYTEFTPTEKDEYAC (-dehydro) RVNHVTLSPKIVKWDRDI (->M).-	β -microglobulin	IVKWDRD	11721.77	7	2.55

*
CS: charge state; ME: molecular mass error (ppm).